Episode 207: In this screen-share, Adam Gefvert, the head analyst from White Diamond Reseach goes over the latest part of a series of short reports unveiling the many problems of Veru Pharma. [NASDAQ: VERU]
Full Short Report: https://whitediamondresearch.com/research/part-2-new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/
Social media
David Capablanca
Twitter: reverse_long
Instagram: reverselong